Tampa St. Petersburg, FL, November 9, 2026 — Moffitt Cancer Center has been awarded a significant grant of $47.3 million from the U.S. Economic Development Administration. This funding is earmarked for the establishment of a new cancer innovation hub, with a strategic focus on developing the Tampa Bay region into a leading radiopharmaceutical hub.

The initiative will be primarily located at Moffitt’s Speros campus in Land O’ Lakes. Radiopharmaceuticals are drugs that combine a radioactive isotope with a targeting molecule, used in both diagnosis and treatment of diseases like cancer.

The project aims to foster advancements in cancer therapy development. This includes plans for building necessary manufacturing facilities to produce these specialized therapies. Furthermore, a key component of the grant’s objectives involves training and developing a skilled workforce capable of supporting this growing field.

To achieve these comprehensive goals, Moffitt Cancer Center is collaborating with several key regional partners. These include the University of South Florida, Pasco-Hernando State College, and Embarc Collective. Each partner brings distinct expertise, contributing to the multifaceted nature of this cancer innovation initiative.

The University of South Florida is expected to contribute its research capabilities and academic expertise. Pasco-Hernando State College will likely play a role in developing educational programs and vocational training pathways. Embarc Collective, an innovation hub itself, is anticipated to support the entrepreneurial and commercialization aspects of the new therapies and manufacturing efforts.

This grant represents a substantial investment in the future of cancer treatment and research within the Tampa Bay area, positioning it as a center for radiopharmaceutical innovation.


Story summarized from the original created by By Camila Jose Gomez, Times staff on www.tampabay.com, see more information here.

Media gallery

SignalNewsAI
About The Author
SignalNewsAI